Thong KY, Gupta PS, Blann AD, Ryder RE
The 0.5mg assessment dose at the beginning is particularly valuable for researchers who have never used any incretin-based peptide before, as it reveals individual sensitivity before committing to the standard 1mg starting dose
Drug interactions of exenatide were described in eight manuscripts [13, 20,21,22,23, 25, 33, 34], liraglutide in five [17, 19, 24, 26, 34], semaglutide in three [16, 18, 27], and lixisenatide, dulaglutide and albiglutide in two each [14, 15, 29,30,31,32] and synthetic GLP1 in one manuscript [28]
rs9357296 versus rs10305420 r 2 = 0.75), neither signal included the coding variant within the 99% credible set 16
Please check any stats or information if you are unsure how accurate they are
No clinical trial data exists for either medication at those exposure levels